Articles tagged with Cancer Cells
A recent study by MUHC and McGill University has shed light on the mechanisms triggering cancer cell growth, potentially leading to targeted therapies. The research discovered that ubiquitin promotes interactions between proteins Cb-b, which plays a crucial role in mitigating uncontrolled cell proliferation.
Researchers at Florida State University have developed a new approach to targeting cancer cells using light-activated molecules that can induce apoptosis in both strands of DNA. By exploiting the unique property of these molecules, they can selectively kill cancer cells while sparing healthy ones.
Researchers at Tufts University have identified a specific DNA sequence that increases chromosome breakage and stalls replication, which can lead to cancer. The study's findings suggest that this sequence may be responsible for the fragility in human chromosomes associated with common fragile sites.
Researchers found that low doses of THC can facilitate infection of skin cells and promote cellular events leading to malignancy, raising concerns for those with lowered immune systems. The study emphasizes the need for caution when using marijuana medicinally or recreationally among vulnerable populations.
Researchers at the University of York have developed urothelial cell sheets that regenerate to repair damage, paving the way for engineered bladders. Pharmaceutical companies will soon be able to test therapies using these models.
Researchers at the University of Texas M.D. Anderson Cancer Center discovered that a protein called IKK-alpha protects an important cell defense mechanism from silencing in skin cancers. The protein prevents DNA methylation, which normally silences the checkpoint gene 14-3-3-sigma.
Researchers at the University of Florida have developed a new method to detect subtle differences in leukemia cells using molecular probes called aptamers. This technique has the potential to improve diagnosis and treatment for cancer patients by providing more precise and personalized care.
Scientists have discovered that cancer cells eliminate the enzyme protein kinase G (PKG), leading to uncontrolled cell proliferation. Reintroducing PKG into cancer cells has been shown to inhibit tumor growth and angiogenesis, suggesting a potential new avenue for targeted cancer treatment.
A Penn State research team discovered that blocking km23, a traffic cop protein, disrupts the transport of a signaling component to the nucleus, leading to reduced gene expression and cell growth. The findings may lead to diagnostic tools and earlier treatments for ovarian cancer.
Scientists have identified a specific pathway, reactive-oxygen species (ROS), that allows cancer cells to evade the immune system. By targeting this pathway, researchers hope to develop new therapies that can break through the 'escape hatch' and accelerate or slow down T-cell activity.
Researchers at the University of Pennsylvania School of Medicine identified a combination therapy that selectively eliminates cancer cells while leaving healthy cells intact. The therapy combines TRAIL and sorafenib, reducing tumor size in mice with few side effects, demonstrating its potential effectiveness on human colon cancers.
Researchers developed a new cancer treatment called Chlorotoxin:Cy5.5, which can illuminate tumor cells in the operating room, making it easier for surgeons to remove all cancerous cells without injuring surrounding healthy tissue. This technology has the potential to improve cancer therapy and save lives.
Scientists at Fred Hutchinson Cancer Center discovered a modified version of antimycin that selectively kills cancer cells with high levels of survival proteins Bcl-2 and Bcl-xL. The compound's unique mechanism provides a therapeutic window, making it a potential targeted molecular therapy to enhance cancer treatment effectiveness.
Researchers characterized transformation mechanisms in APL, revealing the importance of higher-order RXR homotetrameric complexes and recruitment. These findings suggest that disrupting these pathways may be a viable strategy for treating RARA fusion-mediated cancers.
Researchers at Virginia Tech and UC Berkeley developed irreversible electroporation (IRE) to target cancer cells, successfully abling tissue in rat livers. IRE preserves vessel architecture and kills cells with minimal damage to surrounding healthy tissue.
USC researchers applied nanoscale imaging to study Anabaena oscillarioides, clarifying the mechanism of nitrogen fixation. The study revealed a key step in the nutrient cycle, allowing for better understanding of global carbon and nitrogen dynamics.
Delft scientists observe topotecan's effect on DNA molecule loops, revealing mechanism of TopoIB protein in cell division. They use magnetic spheres and magnets to manipulate a single DNA molecule, allowing them to study the enzyme's action live.
Researchers have developed multifunctional nanoparticles that target and image cancer cells by exploiting overexpression of folic acid receptors. These dendrimer-based systems can accumulate in diseased cells and retain bright fluorescence, allowing for easy visualization via confocal microscopy.
Researchers at Goethe University Frankfurt have identified a novel Ub conjugation reaction that allows for more efficient manipulation of key proteins in the treatment of cancer and other diseases. This discovery provides a basis for novel therapeutic approaches that are more specific than existing drugs like Bortezomib.
Scientists create a new adenovirus that selectively targets cancer cells with high dNTP concentrations, potentially delivering genetic materials to destroy malignant cells. The approach has shown promise in testing mice and human pancreatic cancer cells.
Researchers at Vanderbilt University Medical Center discovered that the Golgi apparatus is a novel source of microtubules in cells, which are crucial for cell movement and division. This finding could lead to new insights into cancer cell invasion and treatment strategies.
Researchers at Louisiana State University studied the effects of gold-based nanoparticles on cell freezing, which could impact cancer treatment. Despite initial expectations, the study found significant damaging interaction between nanoparticles and cancer cells.
Researchers have successfully observed cell migration in real-time using a specialized liquid culture medium, shedding light on the nuances of organized cell movement. This breakthrough could lead to strategies for regulating both normal growth and cancer progression.
GSK has launched a Phase III trial evaluating its novel immunotherapy MAGE-A3 ASCI in patients with stage IB or II NSCLC. The trial aims to assess the efficacy and safety of MAGE-A3 ASCI as adjuvant therapy following surgery.
Researchers at St. Jude Children's Research Hospital discovered that cancer cells can increase GAPDH production to counteract the backup self-destruct program CICD, allowing them to survive and thrive. The finding suggests that blocking this enzyme could kill abnormal cells, providing a basis for novel anti-cancer drugs.
Researchers found that the p53 gene activates microRNA miR-34a, which kills cells with damaged genes. This microRNA plays a crucial role in stopping tumor development and is often missing in pancreatic cancer cells.
A study at the University of Pittsburgh School of Medicine found that green tea's catechins protected normal and cancerous bladder cells from inflammation. The findings suggest herbal supplements from green tea could be a treatment option for various bladder conditions.
Two UI studies show that the NSAID celecoxib has potent anticancer activity, killing head and neck cancer cells in the S phase of the cell cycle. This finding suggests that combining celecoxib with chemotherapies may provide better tumor control than radiation alone.
Research suggests that TRPM8 is overexpressed in prostate cancer cells, indicating its potential as a therapeutic target. The study also found that endoplasmic reticulum TRPM8 retains functional activity regardless of cell differentiation status, which may contribute to cancer cell growth.
Researchers created a dynamic model to understand cellular signaling pathways in C. elegans, revealing gaps in current understanding and potential for future exploration of biological systems. The model can predict how cells respond to gene mutations and signals, saving laboratory time and resources.
Researchers found that FDG-PET imaging can identify patients who respond to chemotherapy, allowing for early termination of futile treatment. This improves patient care by providing an alternative approach, such as stopping chemotherapy or switching to a more adequate therapeutic option.
Researchers identified a genetic mechanism that permanently shuts down crucial genes in healthy immune system cells, which could be used to target cancer and infection treatments. The discovery was made in normal blood samples and found in a quarter of leukemia samples, highlighting the potential for this mutation as a therapeutic target.
Researchers have developed a method to analyze the entire network of signaling proteins controlling cell movement. The study provides the first comprehensive profile of these proteins, shedding light on the inner workings of the 'steering wheel' that drives cells forward.
Researchers at Johns Hopkins found that cancer cells can reprogram themselves to use less oxygen and more glucose, allowing them to survive and spread. The loss of a single gene causes cancer cells to stop making mitochondria, leading to the use of fermentation for energy production.
UK pharmaceutical sciences graduate student Abby Ho and assistant professors Kyung-Bo Kim and Royce Mohan developed a new compound dubbed UK-101 that acts directly on LMP2, a component of the immune proteasome variant abundantly expressed in certain tumors. The researchers found that UK-101 inhibits LMP2 while not attacking normal cell...
A Johns Hopkins team has discovered that shortening chromosome ends, called telomeres, can prevent cancer cells from growing by inducing a process known as senescence. This breakthrough could lead to new ways of preventing or treating cancer.
A new study suggests that targeting the survival protein Mcl1 may be an effective way to treat leukemia, particularly when combined with existing drugs like rituximab. The research found that knocking out Mcl1 can cause cancer cells to die, and combining it with rituximab killed significantly more leukemia cells than the drug alone.
A mouse model has been developed to study the relationship between hypoxia and cancer progression in renal cell cancer. The researchers observed that Fh1-deficient mice developed clonal and proliferative renal cysts with characteristic overexpression of HIF, leading to renal failure.
Researchers are investigating a genetically modified variant of Avian Newcastle disease virus to treat human prostate cancer. The virus is designed to replicate only in the presence of prostate-specific antigen, found exclusively in cancerous cells.
Researchers at Samuel Lunenfeld Research Institute have discovered a connection between sugar modifications on proteins and cancer. The study shows how these modifications control protein availability, affecting cell behavior and tumor growth.
Karl Scheidt and his team have synthesized 10 different flavanones, a type of flavonoid, using a new general method that takes advantage of one simple catalyst. The findings provide a method for making new molecules based on flavonoids, setting the stage for the development of new cancer therapeutics.
Researchers at the University of Pennsylvania School of Medicine have demonstrated that injured pancreatic cells readily regenerate back into healthy acinar cells. This finding holds promise for treating cancer and inflammation of the pancreas, while shifting focus from regenerating insulin-producing beta cells.
A recent study found that reducing calorie intake later in life can induce health and longevity benefits similar to lifelong calorie reduction. The researchers discovered that certain drugs mimic this effect, which may lead to the development of new
Scientists discovered a protein that enables cells to bypass damaged DNA during replication, averting cell suicide. However, this protein also makes errors that may contribute to the development of cancer.
A new procedure, anal cytology, detected abnormal cell changes in 244 HIV-positive patients, leading to subsequent biopsy confirmations. Abnormal results prompt further investigation and management.
Scientists at Dana-Farber Cancer Institute mapped the structures of small molecules and mutated protein receptors in non-small cell lung cancer cells. They found that two inhibitors bind more tightly to specific mutations, potentially leading to more effective treatments.
A study published in Cancer Cell reveals that a specific sequence of genetic mutations determines the behavior of cystic pancreatic cancer, which has a 50% long-term survival rate. The research found that cells with this mutation are resistant to TGFb's tumor-promoting properties, contributing to their improved survival.
Researchers found that vitamin A derivative ATRA increases levels of miRNA-15b and miRNA-16-1, which inhibit Bcl-2 gene activity. This helps explain how the drug works by regulating genes that need to be silenced for cell differentiation.
Researchers identified 50 genes that interfere with genetic activities of genes causing uncontrolled cell division. These genes work by producing proteins that directly attach to cell-division genes, hindering their activity.
Research by Cold Spring Harbor Laboratory finds that harmless viruses can cause cancer through chromosomal instability, potentially leading to cancer progression. Protecting against these viruses may decrease cancer incidence.
Researchers used a microfluidic chip to study the mating habits of yeast cells, revealing that a second MAPK plays a crucial role in the process. The findings shed new light on how cells send and receive signals from one another and from their environment.
Researchers identified a new route to cancer treatment by exploiting mutations that control cell movement. Understanding the collaboration between Ras and p53 genes may lead to novel therapeutic targets like Rho proteins.
Robert C. von Borstel presents cancer as an invasive process similar to species evolution, with mutations and selection driving its progression. He hopes his work will help people re-examine cancer in a new light.
Researchers at TRIUMF are developing custom radioisotopes to target cancer cells more efficiently. They aim to create tailor-made treatment programs for each patient, reducing radiation doses and treatment sessions.
Researchers have found a way to deliver a messenger into cancer cells that forces them to respond to death signals using an HIV protein. This approach has shown promise in killing cancer cells and could provide new treatment options for patients with deadly cancers.
A new study finds that p38-alpha MAPK inhibits tumor formation by sensing oxidative stress and triggering apoptosis. Cancer cells may evade this mechanism by desensitizing p38-alpha to ROS, highlighting potential therapeutic targets for cancer treatment.
A new medical technique using microsecond electrical pulses has been shown to create permanent nanoscale holes in target cell membranes without harming surrounding tissue. This technique, called irreversible electroporation (IRE), has the potential to revolutionize minimally invasive surgical treatments for tumors.
Purdue University researchers use dendrimers to label specific proteins in living cells, allowing them to determine protein functions and diagnose diseases. This new method provides a more reliable alternative to existing methods, which require small sample amounts and damage the natural environment.
Researchers developed a small-molecule inhibitor of Plk1, a key kinase controlling cell division. The compound BI 2536 effectively halts cancerous cell growth in culture and in animal models, causing cell death and tumor regression. This discovery has therapeutic potential for patients with locally advanced or metastatic cancers.
Researchers at Oncolytics Biotech have developed a harmless virus that not only kills tumor cells but also primes the immune system to mount a powerful defense against cancer. Studies have shown that reovirus exposure can activate dendritic cells, which then educate natural killer cells and T cells to attack the tumor.